Effects of combined levosimendan and vasopressin on pulmonary function in porcine septic shock
This study aims to determine whether levosimendan combined with arginine vasopressin infusion supplemented with norepinephrine can improve hemodynamics and pulmonary dysfunction. The study was tested in a fecal peritonitis-induced septic shock model, we observed that levosimendan combined with arginine vasopressin supplemented with norepinephrine therapy resulted in lower mean pulmonary artery pressure, lactate concentrations, arterial total nitrate/nitrite, and high-mobility group box 1 levels; decreased lung wet/dry ratio, and pulmonary levels of interleukin-6, total histological scores, and improved pulmonary gas exchange when compared with norepinephrine group. Levosimendan combined with arginine vasopressin supplemented with norepinephrine infusion shows potential benefit in sepsis-induced acute lung injury by decreasing mean pulmonary artery pressure and attenuating inflammatory responses in the lung compared to norepinephrine infusion alone.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2012 |
|---|---|
| Erschienen: |
2012 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
Inflammation - 35(2012), 3 vom: 07. Juni, Seite 871-80 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ji, Muhuo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
113-79-1 |
|---|
| Anmerkungen: |
Date Completed 17.09.2012 Date Revised 20.10.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10753-011-9388-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM211605778 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM211605778 | ||
| 003 | DE-627 | ||
| 005 | 20231224013907.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10753-011-9388-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0705.xml |
| 035 | |a (DE-627)NLM211605778 | ||
| 035 | |a (NLM)21932058 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ji, Muhuo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effects of combined levosimendan and vasopressin on pulmonary function in porcine septic shock |
| 264 | 1 | |c 2012 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.09.2012 | ||
| 500 | |a Date Revised 20.10.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a This study aims to determine whether levosimendan combined with arginine vasopressin infusion supplemented with norepinephrine can improve hemodynamics and pulmonary dysfunction. The study was tested in a fecal peritonitis-induced septic shock model, we observed that levosimendan combined with arginine vasopressin supplemented with norepinephrine therapy resulted in lower mean pulmonary artery pressure, lactate concentrations, arterial total nitrate/nitrite, and high-mobility group box 1 levels; decreased lung wet/dry ratio, and pulmonary levels of interleukin-6, total histological scores, and improved pulmonary gas exchange when compared with norepinephrine group. Levosimendan combined with arginine vasopressin supplemented with norepinephrine infusion shows potential benefit in sepsis-induced acute lung injury by decreasing mean pulmonary artery pressure and attenuating inflammatory responses in the lung compared to norepinephrine infusion alone | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Hydrazones |2 NLM | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 650 | 7 | |a Nitrates |2 NLM | |
| 650 | 7 | |a Nitrites |2 NLM | |
| 650 | 7 | |a Pyridazines |2 NLM | |
| 650 | 7 | |a Arginine Vasopressin |2 NLM | |
| 650 | 7 | |a 113-79-1 |2 NLM | |
| 650 | 7 | |a Lactic Acid |2 NLM | |
| 650 | 7 | |a 33X04XA5AT |2 NLM | |
| 650 | 7 | |a Simendan |2 NLM | |
| 650 | 7 | |a 349552KRHK |2 NLM | |
| 650 | 7 | |a Norepinephrine |2 NLM | |
| 650 | 7 | |a X4W3ENH1CV |2 NLM | |
| 700 | 1 | |a Li, Renqi |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Guo-min |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Yunxia |e verfasserin |4 aut | |
| 700 | 1 | |a Dong, Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Jianjun |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Yong G |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Jing |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Inflammation |d 1975 |g 35(2012), 3 vom: 07. Juni, Seite 871-80 |w (DE-627)NLM000293016 |x 1573-2576 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2012 |g number:3 |g day:07 |g month:06 |g pages:871-80 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10753-011-9388-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2012 |e 3 |b 07 |c 06 |h 871-80 | ||